Phase 4
Completed N=32
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
Source: ClinicalTrials.gov NCT02981966 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Jun 2023
Primary outcomePrimary: Endogenous Glucose Production Measurement — 155; 121; 104; 98 mg/dl
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Researchers hope to determine the organ (liver and/or kidney) responsible for the increase in endogenous glucose production (EGP) following the induction of glucosuria (when glucose is excreted in detectable amounts in the urine) with an SGLT2 inhibitor, dapagliflozin.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Endogenous Glucose Production Measurement |
155; 121; 104; 98 | — |
| SECONDARY Renal Glucose Production Measurement of Change |
0.09; 0.01; 0.03; 0.03; 0.17; 0.03 | — |
Eligibility Criteria
Inclusion Criteria
- 25-35 kg/m^2
- Normal Glucose Tolerance subjects (24)
- Type 2 Diabetic Subjects (24)
- Diabetic subjects must be on a stable dose (more than 3 months) of monotherapy or combination therapy with metformin and/or a sulfonylurea
- Diabetic subjects must have HbA1c 1.4 females or >1.5 males, or 24-hour urine albumin excretion > 300 mg will be excluded.
Data sourced from ClinicalTrials.gov (NCT02981966). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.